Financial Data and Key Metrics Changes - Total revenue for 2025 reached $875.3 million, an 82% increase from $479.9 million in 2024 [5][22] - Net income increased to $70.8 million compared to $52.1 million in 2024 [5][28] - Adjusted EBITDA rose to $259.6 million, up 152.6% from $102.8 million in 2024 [6][29] - Cash on hand grew to $186 million as of December 31, 2025, up from $41 million a year earlier [8][42] Business Line Data and Key Metrics Changes - Hospital division revenue was $844.2 million in 2025, with mature hospitals increasing revenue by 73.4% [22][24] - Total patient visits increased to 188.3 thousand, an 11.8% rise from 168.4 thousand in 2024 [7][24] - Population health division revenue grew slightly by 0.7% to $31 million in 2025 [24] Market Data and Key Metrics Changes - The company reported a decrease in the current portion of long-term debt from $14.4 million to $13.3 million, while net long-term debt increased from $22.5 million to $29.2 million [8] - The ineligible claim submission rate for Nutex Health is approximately 8%, significantly better than the national average of 19% [10][38] Company Strategy and Development Direction - The company is focused on four priority areas: share repurchases, growth at existing hospitals, expansion of the Independent Physician Association (IPA), and real estate development strategy [15][18] - Nutex Health plans to open new hospitals in Jacksonville, West Little Rock, and San Antonio in 2026, with additional facilities planned for 2027 and 2028 [19][71] - The company aims to enhance its operational infrastructure to support higher throughput and a more diversified patient mix [49][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate regulatory challenges and optimize the Independent Dispute Resolution (IDR) process [20][63] - The company is optimistic about its growth trajectory entering 2026, supported by strong liquidity and operational improvements [20][42] Other Important Information - The company recognized a one-time $55 million revenue reduction related to arbitration claims deemed ineligible [9][30] - Total stock compensation expense for 2025 was $117 million, a significant increase from $16.6 million in 2024 [26] Q&A Session Summary Question: IDR-related submission rates and collection rates - The company noted a shift in IDR submission rates from 60%-70% to 50%-60%, with improved collection rates around 85% [56][60] - Management indicated that fewer submissions may reflect higher quality claims leading to better collections [62][65] Question: Reopening of a hospital in Texas - The decision to reopen was based on improved reimbursement through the IDR process and increased volume expectations [67][68] - Management confirmed they remain on track to open 5 to 6 facilities in 2026 and discussed a new real estate strategy to support this [71][72] Question: Timing of learning about the true-up adjustment - The company learned about the true-up adjustment in the middle of the fourth quarter, which was new information that required analysis before communication [77][79]

Financial Data and Key Metrics Changes - Total patient visits increased to 45,573 in Q2 2025, a 10.6% increase from 2024, and total patient visits for the first half of 2025 reached 93,842, a 15.5% increase from 2024 [7][36] - Total revenue for Q2 2025 was $244,000,000, up 220% from $76,100,000 in Q2 2024, with gross profit at $124,800,000 or 51.1% of total revenue compared to $22,600,000 or 29.7% in the same period of 2024 [7][30] - Adjusted EBITDA for Q2 2025 was $73,300,000, compared to $6,800,000 in Q2 2024, indicating significant operational improvement [7][34] - Net cash from operating activities for the first half of 2025 was $78,200,000, compared to $16,300,000 in the same period of 2024 [8] Business Line Data and Key Metrics Changes - The hospital division generated $236,300,000 in revenue for Q2 2025, a 350% increase from $76,100,000 in Q2 2024, with independent dispute resolution revenue accounting for approximately 71% of this [30] - Revenue from mature hospitals increased by 203% in 2025 compared to 2024 [30] - The population health division revenue increased by 9.2% to $7,700,000 in Q2 2025 from $8,500,000 in Q2 2024 [31][44] Market Data and Key Metrics Changes - Total visits at the hospital division for the first half of 2025 were 93,842, an increase of 15.5% from 81,276 in the same period of 2024 [36] - The company collected $311,000,000 in cash for the first half of 2025, with approximately 55% related to arbitration revenue [36] Company Strategy and Development Direction - The company is focused on expanding its micro hospital model, with over 15 hospital projects in development, including two confirmed openings by the end of 2025 [22] - The strategy includes launching one to two independent physician associations (IPAs) annually to enhance care coordination [22][43] - A stock repurchase program of up to $25,000,000 has been authorized to enhance shareholder value [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued evolution and efficiency of the federal arbitration process, which is critical for revenue cycle management [19] - The company is navigating industry trends while remaining committed to delivering value to patients and shareholders [22] - Management highlighted the importance of compliance with the No Surprises Act and the independent dispute resolution process to secure fair compensation [9][12] Other Important Information - The company is addressing a delay in filing its Q2 2025 10-Q due to reevaluation of accounting treatment for stock-based compensation obligations [25][26] - The estimated impact of corrections on total liabilities is projected to increase by approximately $10 to $50 million, with a corresponding decrease in reported equity [28] Q&A Session Summary Question: Timeline for restatement process and filing amended reports - Management is actively working on the restatement and aims to complete the necessary filings within the 60-day timeline provided by Nasdaq [55][56] Question: Collection rates and recourse for arbitration awards - The company has collected over 75% of arbitration awards and is working to improve collection rates further, with various approaches to ensure timely payments from insurers [58][63] Question: Updates on new hospital openings and strategies for mature hospitals - Two new hospitals are expected to open in late 2025, while efforts are being made to retain patients in mature hospitals to increase revenue [69][72] Question: EBITDA margin and factors affecting it - The EBITDA margin has been affected by increased supplier payments and arbitration costs, but overall cash collections remain strong [77][80] Question: Revenue per visit and organic growth - Revenue per visit has seen low single-digit growth from an organic perspective, with ongoing monitoring of reimbursement trends [81][82]

Core Viewpoint - Nutex Health Inc. shares fell by as much as 24% following the announcement of a delay in submitting financial results for Q2 2025, linked to an investigation into potential securities violations [1][3]. Financial Performance and Investigations - Nutex Health has acknowledged a decline in average payments from insurers for out-of-network emergency services, reporting a 26% decrease by the end of 2022 and a further 19% decrease by the end of 2023 [7]. - The company engaged a third-party IDR vendor on July 1, 2024, to manage out-of-network claims, which led to a refinement in revenue recognition timing, increasing revenue by approximately $169.7 million and net income before tax by $112.0 million for the year ended December 31, 2024 [8]. - Hagens Berman has initiated an investigation into whether Nutex misled investors regarding its financial health and accounting practices in light of the anticipated changes in results [11]. Market Reactions and Activist Reports - The stock experienced a significant decline on July 22, 2025, due to a report from Blue Orca Capital questioning Nutex's financial practices and its relationship with the IDR vendor HaloMD [4][9]. - Blue Orca's report suggested that Nutex could revert to penny stock status and highlighted concerns over the collectability of recognized revenue, indicating that a majority of it may be uncollectible [10]. Regulatory Context - The controversy surrounding Nutex is linked to the No Surprises Act, which has impacted healthcare providers' revenue streams by protecting consumers from unexpected medical bills [6].

Core Viewpoint - Nutex Health Inc. shares fell by as much as 24% following the announcement that the company would not submit its financial results on time due to an ongoing investigation into potential securities violations [1][5][11] Financial Performance and Investigations - Nutex Health confirmed a significant change in operational results compared to the previous fiscal year, raising concerns among investors [3] - The company has faced scrutiny due to a decline in average payments from insurers for out-of-network emergency services claims, with a 26% decrease by the end of 2022 and an additional 19% decrease by the end of 2023 [7] - An investigation by Hagens Berman is underway to determine if Nutex misled investors regarding its financial health and accounting practices, particularly in light of anticipated changes in results [5][11] Regulatory and Legal Context - The controversy surrounding Nutex is linked to the No Surprises Act (NSA), which has impacted healthcare providers' revenue streams since its implementation on January 1, 2022 [6] - Nutex's engagement with a third-party IDR vendor to manage out-of-network claims has raised questions about its revenue recognition practices [8][9] Market Reactions and Analyst Opinions - A report from Blue Orca Capital criticized Nutex's financial practices and suggested that the company could revert to penny stock status, indicating severe operational and net losses in 2022 and 2023 [9][10] - Concerns were raised about the collectability of Nutex's recognized revenue, with a significant receivables balance putting the company at risk [10]